Benign thyroid disease in pregnancy: A state of the art review by Tingi, Efterpi et al.
Benign thyroid disease in pregnancy: A state of the art review
Efterpi Tingi a, Akheel A. Syed b,c, Alexis Kyriacou d,e, George Mastorakos f,
Angelos Kyriacou b,e,*
a Obstetrics and Gynaecology, St Mary’s Hospital, Manchester, UK
b Endocrinology and Diabetes, Salford Royal NHS Foundation Trust, Salford, Greater Manchester, UK
c Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
d School of Health Sciences, University of Stirling, Stirling, UK
e CEDM Centre of Endocrinology, Diabetes & Metabolism, Limassol, Cyprus
f National and Kapodistrian University of Athens, Athens, Greece
A R T I C L E I N F O
Article history:
Received 13 September 2016
Received in revised form 8 November 2016
Accepted 10 November 2016
Keywords
Pregnancy
Hyperthyroidism
Hypothyroidism
Thyroiditis
Autoimmune thyroid disease
Thioamides
Iodine
A B S T R A C T
Thyroid dysfunction is the commonest endocrine disorder in pregnancy apart from diabetes. Thyroid hor-
mones are essential for fetal brain development in the embryonic phase. Maternal thyroid dysfunction
during pregnancy may have signiﬁcant adverse maternal and fetal outcomes such as preterm delivery,
preeclampsia, miscarriage and low birth weight. In this review we discuss the effect of thyroid disease
on pregnancy and the current evidence on the management of different thyroid conditions in pregnan-
cy and postpartum to improve fetal and neonatal outcomes, with special reference to existing guidelines
on the topic which we dissect, critique and compare with each other.
Overt hypothyroidism and hyperthyroidism should be treated appropriately in pregnancy, aiming to
maintain euthyroidism. Subclinical hypothyroidism is often pragmatically treated with levothyroxine, al-
though it has not been deﬁnitively proven whether this alters maternal or fetal outcomes. Subclinical
hyperthyroidism does not usually require treatment and the possibility of non-thyroidal illness or ges-
tational thyrotoxicosis should be considered.
Autoimmune thyroid diseases tend to improve during pregnancy but commonly ﬂare-up or emerge
in the post-partum period. Accordingly, thyroid auto-antibodies tend to decrease with pregnancy
progression.
Postpartum thyroiditis should be managed based on the clinical symptoms rather than abnormal bio-
chemical results.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Thyroid disease, after diabetes, is the commonest endocrine dis-
order during pregnancy. The background prevalence of spontaneous
hypothyroidism is between 1% and 2% in iodine-replete commu-
nities; it is 10 times more common in women than in men [1];
subclinical hypothyroidism, deﬁned as a raised serum thyroid stimu-
lating hormone (TSH) levels in presence of normal thyroid hormone
levels, affects about 8% of women. Similarly, the prevalence of hy-
perthyroidism in women is between 0.5% and 2%, and is 10 times
more common than in men in iodine-replete communities [1]; sub-
clinical hyperthyroidism, deﬁned as low serum TSH in the presence
of normal thyroid hormone levels and in the absence of hypotha-
lamic and pituitary disease or non-thyroidal illness or medications
that inhibit TSH secretion, affects about 3% of the population. This
reviewwill explore the interplay between thyroid disease and preg-
nancy and the evolving evidence on themanagement of the different
thyroid conditions in pregnancy and the postpartum period, with
special emphasis on existing guidelines on this ﬁeld.
Methods
We undertook a focused review of the literature and discus-
sions with colleagues. We carried out a search of the published
literature in Medline, PubMed (www.pubmed.gov) and Google
Scholar (www.scholar.google.com) with a broad range of combi-
nations of the medical subject headings (MeSH) terms, ‘pregnancy’,
‘miscarriage’, ‘breastfeeding’, ‘thyroid diseases’, ‘hypothyroidism’, ‘thy-
rotoxicosis’, ‘hyperthyroidism’, ‘anti-thyroid drugs’, ‘carbimazole’,
‘methimazole’, ‘propylthiouracil’, ‘thyroiditis’, ‘post-partum thy-
roiditis’, ‘autoimmune thyroid disease’, ‘non-thyroidal illness’, ‘thyroid
function tests’, ‘congenital malformations’ and ‘neurodevelopmental
defects’. Inclusion criteria were ‘English language’ and articles re-
trieved from 1960 to December 2015. References of articles included
were read to identify any further articles that were missed from the
above database searches and personal archived references were also
sought. Whenever available, we gave preference to meta-analyses,
systematic reviews, randomised controlled trials (RCTs) and pro-
spective epidemiological studies. As appropriate, we included
retrospective and non-randomised studies, and case reports.
Thyroid physiology in pregnancy
Approximately 94% of thyroid hormones are secreted by the
thyroid gland as thyroxine or tetraiodothyronine (T4) and 6% as tri-
iodothyronine (T3) (Fig. 1). T4 is catalytically converted to the more
metabolically active T3 in peripheral tissues by deiodinases and a
portion of peripherally-produced T3 returns to the circulation and
it is because of this peripheral conversion that the plasma T4 to T3
ratio is approximately 4:1 [2,3]. Both T4 and T3 are mostly bound
to carrier proteins in the serum, chieﬂy thyroxine-binding globu-
lin (TBG). However, it is the free hormones (free T4 (fT4) and free
T3 (fT3)) that are available to be actively transported into cells and
exert their effects.
Changes in maternal thyroid function during pregnancy result
from a combination of increased metabolic demands, increased
serum TBG concentrations, stimulation of the TSH receptor by human
chorionic gonadotropin (hCG) [4], an increased mother-to-foetus
transfer of thyroxine and an increased intraplacental breakdown of
T4 and T3 (resulting from the placental expression of deiodinase
3). Total T4 and T3 concentrations increase by 50% as a result of a
50% increase in circulating TBG levels by 6–8 weeks of gestation;
their levels plateau at around 16 weeks of gestation [5]. Maternal
TSH is usually within normal limits during pregnancy but it can be
decreased in the ﬁrst trimester due to the increased hCG levels and
the cross-reactivity of this hormone on TSH receptors [6]; both are
glycoprotein hormones with a common α subunit and a consider-
able homology between their β subunits. Therefore hCG has a weak
thyroid stimulating activity [6]. hCG levels increase following
fertilisation and peak at 10–12 weeks of gestation, leading to a rise
in the total serum T4 and T3 concentrations and subsequently
reduction of thyrotropin-releasing hormone (TRH) and TSH levels
as a result of negative feedback. This hormonal interplay results in
a biochemical picture of subclinical hyperthyroidism, which can be
considered as a physiological ﬁnding. The decrease in hCG secre-
tion later in pregnancy leads to reduction of serum fT4 and fT3
concentrations and ﬁnally the normalisation of TSH levels [4]. Thyroid
hyperfunction and symptoms, if present, subside as hCG produc-
tion falls, typically at 14–18 weeks of gestation. Ideally, the assay-
speciﬁc TSH reference ranges for each trimester should be calculated
based on the local population in iodine suﬃcient areas and preg-
nant women recruited for such calculations should be euthyroid and
thyroid antibody negative. When this is not feasible, a reasonable
alternative is to use the consensus ranges as per the various guide-
lines (Table 1) [7–9]. However, it is worth emphasizing that these
guideline reference ranges are mainly drawn from Western popu-
lations; for example, the TSH in Chinese populations has been shown
to be higher than these reference values [7].
Iodine and pregnancy
Iodine is an essential component of thyroid hormones and re-
quirements increase during pregnancy. Iodine deﬁciency is associated
with thyroid dysfunction and subsequently with impaired fetal de-
velopment [10]. It is nowadays accepted that severe maternal iodine
deﬁciency can have adverse implications for the mother, includ-
ing hypothyroidism and goitre; for the foetus, including miscarriage
and stillbirth; for the neonate, including neonatal mortality; and
for the child, including impaired neurological development, falter-
ing growth and cretinism [10–12]. Iodine supplementation is
recommended as a treatment of maternal hypothyroidism in se-
verely iodine deﬁcient populations and there is good evidence that
38 E. Tingi et al. / Journal of Clinical & Translational Endocrinology 6 (2016) 37–49
it improves clinical outcomes including cretinism and infant mor-
tality rates [11,13].
There have been concerns raised recently for the adequacy of
iodine intake in pregnant and child-bearing age women in the UK
and other developed countries. Some of these areas, thought before
as iodine-replete, were found to be mildly-to-moderately iodine de-
ﬁcient [10,14–19]. Furthermore, new emerging evidence from the
large longitudinal AVON study in the UK has shown that mild-to-
moderate maternal iodine deﬁciency was associated with lower
cognition in their offspring at the age of eight and nine years in a
linear manner [15], conﬁrming the results of a smaller study in Aus-
tralia [20]. Such an association may account for the previously
described relationship between higher (especially oily) ﬁsh intake
in pregnancy and improved cognition in the offspring [21]; indeed
ﬁsh intake seems beneﬁcial for maternal outcomes, such as gesta-
tional hypertension [22], as well as reducing thyroid autoimmunity
in the antenatal and post-partum period [23]. Although such a
favourable effect has been attributed to the omega-3 fatty acid
content of oily ﬁsh [23], it is possible that the high iodine content
of oily ﬁsh is the cause for the beneﬁcial effects on thyroid physi-
ology and function [15]. Nevertheless, iodine supplementation in
pregnant women from areas of mild to moderate iodine deﬁcien-
cy is still debatable. Although the evidence has been encouraging
regarding supplementation in several studies, not all of the studies
had a rigorous methodology [16,24,25]. These studies have sug-
gested that iodine supplementation in mildly-to-moderately iodine
deﬁcient populations have some beneﬁcial effects on maternal and
newborn serum thyroglobulin and thyroid volume (i.e. a smaller in-
crease), while data on thyroid function is inconsistent and hard-
evidence on long-term effects such as pregnancy outcomes,
childhood neurodevelopment and growth are missing [10,25,26].
Limited evidence has shown that earlier initiation of iodine supple-
ments is related to better outcomes [25].
Fig. 1. Hypothalamic-pituitary-thyroid axis and pregnancy.
Table 1
TSH reference ranges in pregnancy.
TSH reference ranges (mU/L)
First
trimester
Second
trimester
Third
trimester
American Endocrine Society 0.1–2.5 0.2–3.0 0.3–3.0
American Thyroid Association
European Thyroid Association <2.5 <3.0 <3.5
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Similarly, no long-term studies have examined the effect of iodine
supplementation during lactation on child development. Never-
theless, an RCT in a moderate-to-severe iodine deﬁciency
mountainous area inMorocco determined that supplementationwith
one dose of 400 mg iodised oil to the mother rather than 100 mg
directly to the nursing infant was more effective in terms of reduc-
ing the frequency of infant thyroid hypofunction [27].
On the other hand, excessive iodine supplementation should be
avoided. There is evidence that over-replacement with iodine could
increase the risk of subclinical hypothyroidism, isolated
hypothyroxinaemia and auto-immune hypothyroidism [13,25]. Fur-
thermore, kelp supplements should be avoided due to their variable,
and sometimes excessive, iodine content [14].
The various guidelines seem to converge on the need for oral
iodine supplementation of 150 μg daily during pregnancy and lac-
tation. It is important to note that these guidelines were based on
urinary iodine concentration which is a population assessment of
iodine status, but not so useful as a tool for the assessment of the
iodine status of an individual [13].
Thyroid physiology in utero
Thyroid hormones are essential for fetal brain development in
the early embryonic phase; therefore, thyroid dysfunction during
pregnancy may have signiﬁcant adverse maternal and fetal out-
comes (Table 2). That is because the fetus relies on maternal thyroid
hormones during the crucial period of brain development. The fetal
thyroid gland starts producing both T4 and T3 from about 10 weeks
of gestation [28]; however, until approximately 20 weeks of ges-
tation, the fetal thyroid is not fully active and therefore the fetus
is very dependent on the maternal thyroxine supply [29]. TBG con-
centrations reach adult levels at term. T4 and fT4 concentrations
reach adult levels at approximately 36weeks of gestation, but T3 and
fT3 are always below adult concentrations [30].
Hypothyroidism
Primary maternal hypothyroidism is deﬁned as the presence of
an elevated TSH concentration during gestation in the absence of
rare exceptions such as TSH-secreting pituitary tumour, thyroid
hormone resistance and a few cases of central hypothyroidismwith
biologically inactive TSH [8].
Overt hypothyroidism
Overt hypothyroidism is deﬁned as an elevated serum TSH level
(above the trimester-speciﬁc range) with fT4 below the reference
range; the American Thyroid Association (ATA) is the only society
that incorporated into the deﬁnition a TSH level of 10 mU/L or
greater, irrespective of the fT4 level [8]. It affects 0.3–0.5% of preg-
nancies. It is often pre-existent although it can sometimes develop
during pregnancy. Its commonest cause is chronic autoimmune
(Hashimoto’s) thyroiditis. It can also result from previous surgery
or radioactive iodine treatment for hyperthyroidism, goitre or thyroid
cancer.
Various studies have shown an increased incidence of obstet-
ric complications in pregnant womenwith untreated hypothyroidism
(Table 2). These include preterm birth, low birth weight (mostly
related to preterm delivery), perinatal death, pregnancy induced hy-
pertension, pre-eclampsia, placental abruption, anaemia and
postpartum haemorrhage [31]. Hypothyroidism has also been as-
sociated with adverse effects on intelligence quotient (IQ) and
neuropsychological development [32]. Following the diagnosis of
overt hypothyroidism, levothyroxine replacement should be com-
menced, aiming to achieve a TSH level within the trimester-
speciﬁc pregnancy reference range [8,9] (Fig. 2). The majority of
pregnant women with pre-existing hypothyroidism will need in-
crements of their levothyroxine dose by 25–50%, often within four
to eight weeks of gestation and the dose increment tends to plateau
by 16 weeks of gestation [8,9,33,34]. Such a dose increment should
take place immediately on conﬁrmation of a missed cycle or a pos-
itive pregnancy test; one way of doing this is by increasing the 7
doses of levothyroxine per week to 9 doses [8,34]. The levothyroxine
requirements usually plateau from 16–20 weeks of gestation until
delivery.
Subclinical hypothyroidism
Subclinical hypothyroidism is deﬁned as an elevated TSH level
(TSH 2.5–10.0mU/L) with normal levels of free thyroxine. It can affect
0.25–2.5% of all pregnancies [35,36], albeit in some studies the prev-
alence is even higher likely reﬂecting both differences in the
deﬁnitions used and the populations studied. Subclinical hypothy-
roidism during pregnancy has been associated with signiﬁcantly
increased risk of hypertension and pre-eclampsia, placental
abruption, premature rupture of membranes, early pregnancy loss,
neonatal death and gestational diabetes [37–41]. The risk of mis-
carriage has been conﬁrmed in prospective studies in iodine-
replete populations and the risk seems to apply with TSH increments
above, but not within, the normal range [40]. Neurodevelopmental
deﬁcits in the offspring have been reported in some studies [42,43],
but the evidence for this is inconsistent [44–46]. In the only
interventional study by Lazarus et al., pregnant womenwere divided
into a screening and a control group; the former had blood samples
analysed immediately for thyroid function tests (TFTs) and sub-
clinical hypothyroidism was treated with levothyroxine; the latter
had their TFTs analysed after the end of the pregnancy [47]. There
was no difference between the two groups when their children were
neuropsychologically assessed at the age of three years [47]. However,
this study can be criticised for the fact that the addition of thyroxine
Table 2
Adverse fetal and maternal outcomes associated with maternal thyroid dysfunction.
Overt hypothyroidism Subclinical hypothyroidism Isolated hypothyroxinaemia Overt hyperthyroidism
Fetal outcomes Preterm delivery Prematurity Low birth weight Preterm delivery
Low birth weight Fetal and neonatal death Neuropsychological impairment Intrauterine growth restriction
Miscarriage Neuropsychological impairment† Fetal thyrotoxicosis
Congenital malformations
Fetal death
Maternal outcomes Anaemia Gestational diabetes Placental abruption Pre-eclampsia
Placental abruption Pre-eclampsia Adverse metabolic phenotype‡ Gestational hypertension
Postpartum haemorrhage Premature rupture of membranes Cardiac failure
Gestational hypertension Thyroid storm
† Inconclusive results.
‡ An adverse metabolic phenotype, such as obesity, is more likely to be the cause of isolated hypothyroxinaemia, rather than the other way around.
40 E. Tingi et al. / Journal of Clinical & Translational Endocrinology 6 (2016) 37–49
occurred at a relatively late stage in gestation (at an average of
13 weeks) and one should be aware that a lack of impact at the age
of three does not necessarily translate to a lack of impact at a later
stage in life. Similarly in an as yet-unpublished large multicentre
double-blind RCT of levothyroxine use for subclinical hypothyroid-
ism in pregnancy (at a mean gestational age of 17weeks), there was
no difference in intelligence quotient measurements in the off-
spring at the ages of three or ﬁve years [48]. There is also a scarcity
of studies examining the impact of subclinical hypothyroidism in
children under three years of age [49].
The ATA recommended that women with subclinical hypothy-
roidism who have elevated titres of thyroid peroxidase antibody
(TPOAb) should be treated with levothyroxine based on one study
[8]; however, they commented that there is limited data to either
recommend or discourage levothyroxine treatment for TPOAb neg-
ative women with subclinical hypothyroidism. The RCT in question
by Negro et al. has indeed shown a statistically important reduc-
tion in miscarriages and pre-term deliveries in euthyroid TPOAb-
positive women who received levothyroxine and a reduction of the
trend towards declining fT4 and increasing TSH longitudinally in
gestation [50]. Nevertheless, levothyroxine was commenced on
average at around 10 weeks of gestation and all but one miscar-
riage took place prior to the 12 weeks so it is questionable whether
indeed the thyroxine therapy inﬂuenced this outcome. Further-
more, this study took place in Southern Italy which has some iodine
deﬁciency and hence the ﬁndings cannot be easily extrapolated to
other populations. The European Thyroid Association (ETA) and The
Endocrine Society recommend levothyroxine replacement in all
womenwith subclinical hypothyroidism regardless of TPOAb status,
as they consider the advantages of therapy to far outweigh the po-
tential disadvantages [9,49]. Indeed, the general consensus among
endocrinologists has been to treat all suchwomenwith levothyroxine
to achieve a TSH level within the trimester-speciﬁc range [49].
However, a recent large, population-based prospective Dutch study
has cast doubt on such practices because it revealed an associa-
tion between early pregnancy maternal TFTs and child IQ (at six
years) and brain morphology on MRI (at eight years of age); both
low and high fT4 levels were associatedwith reduced IQ and reduced
grey matter and cortical volume [51]. Hence, the authors recom-
mended caution in prescribing levothyroxine for subclinical
Maternal 
Hypothyroidism 
Already on 
thyroxine? 
Yes
Presentation 
within 12 
weeks of 
gestation? 
Yes
Increase 
thyroxine dose 
by 25-30% 
No 
Check TFTs
Is TSH above 
the trimester-
specific  range? 
Yes
Increase dose 
of      thyroxine 
No 
No change in 
dose of 
thyroxine
No 
Check TFTs
TSH 2.5-10 
mIU/L 
Start thyroxine  
e.g. 50µg 
daily† 
TSH >10 mIU/L 
Start thyroxine 
e.g. 100µg 
daily† 
Fig. 2. Treatment of maternal hypothyroidism in pregnancy TFTs, thyroid function tests. TSH, thyroid stimulating hormone. †These are conservative estimates based on our
experience. Higher doses may be required and depending on the patients’ total body weight. We recommend regular TFTs and levothyroxine dose escalation until TSH drops
within the trimester-speciﬁc reference range.
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hypothyroidism given that this often results in high-normal fT4 levels
[51], albeit this study did not speciﬁcally look at the effect of
levothyroxine therapy for subclinical hypothyroidism. Neverthe-
less, based on this study and the general dearth of evidence on the
ability of levothyroxine to counter the complications observed with
subclinical hypothyroidism, a position statement has been pub-
lished by some investigators challenging the existing orthodoxy on
the topic and essentially stating that at present we are not in a good
position to recommend for or against treatment of this pathology
in pregnancy and that further RCTs are necessary to guide prac-
tice [39].
For both overt and subclinical hypothyroidism, it is advisable that
TFTs should be performed regularly, particularly in the ﬁrst half of
pregnancy, and every time there is a change in treatment. There is
usually no requirement for additional fetal surveillance in mothers
with well controlled hypothyroidism. Following childbirth, it is
common practice to reduce the levothyroxine dose to pre-pregnancy
levels immediately post-delivery, although some authors advo-
cate that the dose should be reduced to the pre-pregnancy levels
two weeks post-partum, followed by repeated TFTs [52].
Isolated hypothyroxinaemia
Maternal isolated hypothyroxinaemia (IH) is deﬁned by some
authors as TSH concentrations within normal range and fT4 levels
below the reference range [52], whereas other common deﬁni-
tions include a normal TSH with fT4 in the lowest 2.5th or 5th or
even 10th percentile of the normal pregnant population [49,53]. The
prevalence varies between studies, and given the aforementioned
differences in deﬁnition, from 1.3% to 10% of pregnant women in
iodine suﬃcient regions [44,53–55]. The diagnosis of IH can indi-
cate the early stages of thyroid insuﬃciency and rarely secondary
hypothyroidism, which should always be considered [52]. Some
authors have reported increased rates of IH in areas of mild to mod-
erate iodine deﬁciency and with advancing gestational age, reaching
25% in the third trimester [56,57]. Moreover, a recent study of a large
population of iodine-suﬃcient pregnant women from China has
shown markedly increased risk of IH with iron deﬁciency [58].
Studies have shown that IH is associated with obstetric risks
(Table 2), including placental abruption, low birth weight,
neurodevelopmental impairment and pregnancy loss [52]. Two large
prospective studies have given conﬂicting results regarding the sig-
niﬁcance of IH. Bothmeasured TFTs in the ﬁrst 20weeks of gestation
and compared them to pregnancy outcomes [54,55]. The ﬁrst study
found similar pregnancy outcomes and TPOAb levels between
women with IH and those who were euthyroid [54]. The second
study identiﬁed an increased risk of fetal distress, small-for-
gestational age and musculoskeletal malformations in the offspring
[55]. It is not clear why there is such a discrepancy; admittedly, the
former study had a higher population (about 18,000 vs. 1000women,
respectively), but the classiﬁcation of complicationswas better overall
in the latter study. It is also conceivable that the different populations
Table 3
Comparison of the recommendations of the current guidelines on the management of thyroid disease in pregnancy.
Guideline aspect American Thyroid Association [8,70]* The Endocrine Society [9] European Thyroid Association [7]
Hypothyroidism: levothyroxine
therapy
Treatment is recommended Treatment is recommended Treatment is recommended
Subclinical hypothyroidism:
levothyroxine therapy
Treatment is recommended if TPOAb-
positive;Treatment is discretionary if
TPOAb-negative
Treatment is recommended Treatmet is recommended
Lack of RCT evidence documenting
beneﬁt of levothyroxine therapy in
women with subclinical
hypothyroidism and no antibodies
Potential beneﬁts are considered more
than potential risks
‘Levothyroxine therapy would appear
to have the potential beneﬁts which
outweigh the potential risks’†
Isolated hypothyroxinaemia:
levothyroxine therapy
Treatment is discouraged Treatment is discretionary Treatment is recommended if
diagnosed in the 1st trimester
Treatment is discouraged if diagnosed
in the 2nd and 3rd trimester
‘Management. . .is controversial and
requires further study’
‘. . .partial replacement therapy may be
initiated at the discretion of the
caregiver, with continued monitoring’
Hyperthyroidism: anti-thyroid drugs PTU in the 1st trimester
MMI in the 2nd and 3rd trimester
PTU in the 1st trimester
MMI in the 2nd and 3rd trimester
N/A
PTU in 1st trimester; MMI in the 2nd
and 3rd trimester, or, alternatively,
continue with PTU (ATA 2016 [70])
Subclinical hyperthyroidism: Treatment is discouraged Treatment is discouraged N/A
Treatment is discouraged [70]
Autoimmune Thyroid Disease (TPOAb
positive)
Treatment is discretionary Treatment is discouraged N/A
‘Insuﬃcient evidence to recommend
for or against screening for TPO Abs or
for treatment with LT4 of
TPOAb + euthyroid women. . .’
‘Universal screening for thyroid
antibodies, and possible treatment,
cannot be recommended. . .’ ‡
N/A
Iodine supplementation§ 150 μg in the form of potassium
iodide. Avoid kelp supplements.
150–200 μg in the form of potassium
iodide or iodate. Commence ideally
before conception. Avoid excessive
intake above 500mcg
150 μg. Commence ideally before
conception.
Avoid excessive intake that is 500–
1100mcg
Avoid excessive intake above 500mcg
TPOAb: thyroid peroxidase antibodies; RCT: randomised control trial; PTU: propylthiouracil; MMI: methimazole or carbimazole; N/A: not applicable.
* All these recommendations are derived from the 2011 ATA guidelines [8] for the diagnosis and management of thyroid disease during pregnancy and postpartum, apart
for the recommendations for hyperthyroidism where the 2016 ATA guidelines on thyrotoxicosis were also utilized [70].
† Pre-conception it is reasonable to maintain TSH <2.5 mU/L, especially in those with TPO positivity.
‡ If euthyroid with TPOAb positivity, then TSH should be measured before pregnancy and during the 1st and 2nd trimester.
§ These recommendations are also valid for lactation.
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(US vs. Chinese, respectively) have inﬂuenced these ﬁndings. Another
recent longitudinal cohort study assessed the effect of
hypothyroxinaemia during early pregnancy on school perfor-
mance and concluded that there is an association with subnormal
arithmetic (but not language) performance tests in their offspring
at the age of ﬁve [59]; as with many studies of this kind there was
a large number of cases lost to follow-up, which can introduce at-
trition bias. Another study has reported that IH, but not subclinical
hypothyroidism, is associated with an adverse metabolic pheno-
type in pregnancy, as is decreasing maternal fT4 and increasing
fT3:fT4 ratio [60]. IHwas traditionally left untreated as it was thought
to be a normal variant but nowadays some centres tend to treat it.
Although the ATA guidelines do not recommend treatment [8], and
The Endocrine Society have refrained from giving clear guidance [9],
the ETA guidelines are the only ones which suggested that
levothyroxine supplementation should be considered in the ﬁrst tri-
mester [49], because of the aforementioned association with
neuropsychological impairment in the offspring. However, they do
not recommend treatment after the ﬁrst trimester (Table 3).
Hyperthyroidism
Overt hyperthyroidism, deﬁned as suppressed TSH with el-
evated fT4 and/or fT3 levels, is relatively uncommonduring pregnancy,
occurring in 0.1–0.4% of all pregnancies [61]. A suppressed or unde-
tectable TSH level during pregnancy and especially in the ﬁrst
trimester is usually due to the direct stimulation of the thyroid gland
by hCG which can result in transient gestational thyrotoxicosis. Hy-
peremesis gravidarum, hydatidiform mole, choriocarcinoma and
multiple pregnancies can produce the same effect [62].
Graves’ disease
Graves’ disease (autoimmune hyperthyroidism) is the common-
est cause (in 85% of cases) of overt hyperthyroidism [9,63]; solitary
or multi-nodular toxic nodules or factitious thyrotoxicosis are less
common causes. The disease usually exacerbates within the ﬁrst tri-
mester and improves thereafter, and recurs following delivery [61,64].
This follows the same pattern as other autoimmune conditions
during pregnancy and the puerperium, therefore the dose of
thioamides is often reduced following the ﬁrst trimester.
Differentiation of Graves’ disease from gestational thyrotoxico-
sis is supported by the presence of clinical stigmata of Graves’
disease, such as a typical goitre, ophthalmopathy and pretibial
myxoedema, and the presence of TSH receptor antibodies (TRAbs).
TPOAbmay be present in either case. Thyroid ultrasound may show
enlarged gland dimensions and typical increased blood ﬂow in
Graves’ disease, but there are no absolute differentiating features
from gestational thyrotoxicosis [65]; hence it is not usually essen-
tial. Radioisotope scanning is contraindicated in pregnancy.
Inadequately treated hyperthyroidism is associated with an in-
creased risk of preterm labour, intrauterine growth restriction, pre-
eclampsia and fetal death [66]; fetal malformations have been
reported in most [55,67,68], but not all studies [69]. The explanation
for this discrepancy may be that in the latter study by Yoshihara
et al. patients that received anti-thyroid drugs (ATD) were ex-
cluded from the analysis [69], hence it is conceivable that the milder
spectrum of Graves’ disease is not associated with congenital mal-
formations. In view of adverse fetal outcomes (Table 2), growth scans
should be offered in women with hyperthyroidism; and absence of
fetal tachycardia (<160 beats per minute) must also be docu-
mented at each antenatal visit [66]. The treatment of overt
hyperthyroidism aims to maintain maternal fT4 levels at or slightly
above the upper limit of the trimester- and assay-speciﬁc refer-
ence range or, alternatively, maintain total T4 and T3 levels at or
slightly above the normal reference range in pregnancy or at 1.5 fold
the upper limit of the non-pregnant reference range in the second
and third trimester [70]. TSH below the reference range for preg-
nancy would be acceptable as TSH levels can be misleadingly ‘low’
and consequently lead to overtreatment.
Treatment of Graves’ disease in pregnancy
The use of ATD is recommended for the treatment of Graves’
disease or toxic nodular disease causing overt hyperthyroidism (Fig.
3). Radioiodine therapy is contraindicated in pregnancy. Therapeu-
tic administration of radioiodine to the mother after the fetal gland
is formed (i.e. after about 10weeks into gestation) can result in fetal
hypothyroidism and may be associated with attention deﬁcit
disorders and impairment of ﬁgurativememory in the offspring [71].
Incidentally, when radioiodine therapy is applied in non-pregnant
women, it is recommended to avoid conception for at least six
months.
The ﬁrst line ATD has traditionally been propylthiouracil (PTU).
This is because methimazole (MMI) and carbimazole (CBZ, which
is a prodrug toMMI; the termMMI shall be used to cover both these
medications for simplicity) have been traditionally associatedwith
a higher risk of congenital malformations, whereas PTU was not
thought to increase such risk [69]. However, in other studies
both MMI and PTU use in early pregnancy were associated
with birth defects [72,73], but the risk remained higher with MMI
comparative to PTU (Odds Ratio 1.66 with MMI vs. 1.41 with PTU)
[73]. Moreover, there was differential expression of complications
between the twomedications,withMMI causing ‘MMI-induced em-
bryopathy’ (choanal atresia, oesophageal atresia, omphalocele,
omphalomesenteric tract anomalies and/or aplasia cutis), eye and
urinary tract anomalies, whereas PTU was associated with malfor-
mations in the face and neck region and urinary tract anomalies
[72,73]. Situs inversus, cardiac outﬂow abnormalities and unilat-
eral kidney a/dysgenesis were commoner with PTU use in another
case-affectedcontrol study [74].Data fromtheUKYellowCardScheme
(for reportingmedication adverse effects) documented only six cases
with 11 birth anomalies related to PTU exposure in the past 50 years
[75]; the corresponding number for MMI was 57 cases with 97
anomalies, hence also suggestive of a MMI embryopathy.
Nevertheless, MMI is the agent most widely used outside of preg-
nancy and its administration is more convenient (once daily vs. split
dosing). During the second and third trimester, MMI is recom-
mended in preference to PTU [8,9,70], in view of rare reports of
severe hepatotoxicity with the latter (about 1 in 10,000) [2]. However,
in daily practice switching of ATD can be somewhat ‘messy’ as it
may lead to variations in TFTs in the short-term. Moreover, the case
for such a switch has never been proven [76] and indeed a shift
between PTU and MMI in early pregnancy has recently been linked
with an increased risk of congenital malformations by 82–88%
[73,76]. Moreover, a recent large population-based cohort study that
assessed the complications of ATD has indicated that the inci-
dence of liver dysfunction and agranulocytosis are exceedingly rare
in pregnancy, whereas ATD-induced congenital defects are com-
paratively more frequent (less than one case of agranulocytosis or
liver dysfunction per 5 million population per 10 year period versus
44 live births with birth defects in same time period) [77].
In conclusion, there isn’t much evidence that the switch from
PTU to MMI after the ﬁrst trimester reduces the risk of complica-
tions. Fulminant hepatic failure associated with PTU is vanishingly
rare, but when it occurs is a devastating complication and has been
encountered in both pregnant women and their foetuses. Further-
more, although both PTU andMMI seem to be linkedwith congenital
malformations, the incidence of such defects is higher with MMI
and overall the defects encountered are of a more serious nature.
There is a wide variation in practice for newly diagnosed Graves’
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disease during pregnancy; a survey of ETA members reported that
53% would treat with PTU, 12% with MMI, and only 34% with PTU
initially and switch to MMI after the ﬁrst trimester as per guide-
lines [78]. The very recent ATA guidelines on thyrotoxicosis have
incorporated these gaps in evidence and mention that for females
taking PTU in the ﬁrst trimester they may either switch to MMI or,
alternatively, remain on PTU for the second and third trimester.
Whichever ATD is used the patients should be provided with oral
and written information that if a pruritic rash, jaundice, acolic stools
or dark urine, arthralgias, abdominal pain, nausea, fatigue or fever
were to occur then they have to stop the medications immediate-
ly and inform their physicians [70].
We recommend a discussion with the patient regarding the pros
and cons of these therapies, preferably at pre-conception counsel-
ling. Furthermore, for women who are contemplating pregnancy in
the near-future we encourage them to consider a deﬁnitive therapy,
such as radioidine therapy or surgery, especially if requiring high
doses of ATD as these will abolish the need to for ATD antenatally
[70,79] Radioiodine would be acceptable when pregnancy is con-
templated after at least six months, and thyroidectomy if conception
is envisaged within a six month interval and/or if there is a large
goitre. It is worth noting that TRAb titres increase for at least a year
post-radioiodine therapy (vs. a common, but not universal [80], re-
duction with surgery) [81] and this could theoretically raise the risk
for fetal or neonatal thyrotoxicosis. Hence, surgery may be a more
attractive option for those women with persistently raised TRAb,
especially if planning to conceive within one year [70]. In any case,
regardless of the deﬁnitive therapy employed to treat Graves’ disease,
the patient should be rendered euthyroid through appropriate and
prompt adjustments of levothyroxine, before conception is at-
tempted. Pregnant women should have their TFTs checked regularly
about every 3–4 weeks whilst on PTU treatment, and two weeks
after switching from PTU to CBZ, followed by 2–4 week intervals
until thyroid function is within normal limits [8].
A surgical approach should be considered as a last resort in preg-
nant women with overt hyperthyroidism who are unable to take
ATD because of either a severe adverse reaction or non-concordance.
Moreover, if high doses of ATD (e.g. >30 mg/d of CBZ or >450 mg/d
of PTU) are required to achieve optimal treatment, this may be
another indication for surgical intervention. The optimal timing for
Hyperthyroidism† 
Overt hyperthyroidism 
1st trimester 
Propylthiouracil 
(PTU)
Consider thyroidectomy 
in 2nd trimester if 
>450mg/day needed or 
intolerance or non-
concordance with PTU 
2nd & 3rd trimester 
Methimazole               
(MMI) or, alternatively, 
continue with PTU  
Consider thyroidectomy 
in 2nd trimester if 
>30mg/day needed or 
intolerance or non-
concordance with MMI 
Gestational 
thyrotoxicosis 
Subclinical 
hyperthyroidism 
Avoid treatment 
Observe 
Fig. 3. Treatment of maternal hyperthyroidism in pregnancy. †In most patients hyperthyroidism appears outside of pregnancy and in such cases deﬁnitive treatments with
thyroidectomy or radioidine ablation should be considered if pregnancy is contemplated in the near-future (see main text).
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surgery is the second trimester given the risks of teratogenicity and
miscarriage with ﬁrst trimester and preterm delivery with third tri-
mester surgery.
Breastfeeding and use of anti-thyroid drugs
Formany years breastfeedingwas strongly discouraged inwomen
treated with ATD. However, studies have shown that only limited
quantities of PTU and MMI are secreted in milk, therefore the neo-
natal exposure to ATD is minimal and clinically insigniﬁcant [63,82].
Furthermore, few studies, albeit small-scale, have shown normal TFTs
and no increased risk of malformations in neonates whose mothers
received MMI in pregnancy [83–85]. Hence, women with hyper-
thyroidism using low-to-moderate doses of CBZ (<20 mg) or PTU
(<300 mg) should be encouraged to breastfeed, as the beneﬁts of
breastfeeding largely outweigh the theoretical risks from ATD treat-
ment [86]. The ATD of choice in such circumstances is MMI f [8,70].
Treatment of subclinical hyperthyroidism in pregnancy
In subclinical hyperthyroidism (reduced TSH, normal fT4 and fT3),
treatment should be avoided and consideration should be given
whether this is a normal variant (due to high hCG levels) or, occa-
sionally, due to non-thyroidal illness. In one large study of 25,765
women who underwent thyroid screening and delivered single-
ton infants, subclinical hyperthyroidism (1.7%) was not associated
with adverse pregnancy or neonatal outcomes, and indeed there
was a signiﬁcantly reduced risk of gestational hypertension (but not
severe pre-eclampsia) [54], although it is unclear why this should
be, or indeed if this represents a chance ﬁnding (Table 3).
Gestational hyperthyroidism
Gestational hyperthyroidism is deﬁned as transient hyperthy-
roidism limited to the ﬁrst half of pregnancy, associated with a high
fT4 and a suppressed TSH, but no clinical nor any antibody evi-
dence of thyroid autoimmunity. fT3 is elevated less frequently. It
complicates 0.5–10 per 1000 pregnancies [87].
Regarding hyperemesis gravidarum (characterized by 5% weight
loss, dehydration and ketonuria), various hormonal, mechanical and
psychological factors have been implicated in its pathophysiology.
The current literature suggests three pathophysiological mecha-
nisms: placental growth and function as reﬂected by free hCG,
maternal endocrine function, and pre-existing gastro-intestinal (GI)
disease. The temporal relationship between the level of hCG (peaking
between 6 and 12 weeks) and severity of vomiting suggest hCG per
se may have a causative role [88]. The exact mechanism, however,
for how elevated levels of hCG leads to hyperemesis is unclear. High
levels of estradiol may be implicated, whereas another proposed
mechanism involves the stimulatory effect of hCG on the secreto-
ry pathways in the upper GI tract [89], albeit a decreased gastric
tone and motility due to elevations in progesterone in pregnancy
may also be involved.
The vast majority of patients with hyperemesis gravidarum and
hyperthyroidism do not require ATD. Instead, they should be
managed with supportive measures and their illness should resolve
spontaneously. Clinical judgment should be followed in womenwho
are clinically thyrotoxic or in addition have a serum T4 level above
the reference range for pregnancy. Beta-blockers (such as proprano-
lol or metoprolol) may be used cautiously if very symptomatic, and
always after liaison with the obstetric team.
On rare occasions when gestational hyperthyroidism persists well
into the second trimester with prominent symptomatology and a
biochemical picture of thyrotoxicosis and despite hCG levels that
are relatively low or reducing, in such cases liaising with relevant
research institutions could be considered for sequencing the TSH
receptor gene to look for mutant TSH receptor with enhanced hCG
sensitivity [90,91].
In women with hyperemesis gravidarum and clinical features of
hyperthyroidism, TFTs and TRAbs should be measured. TRAbs have
high sensitivity and speciﬁcity for the diagnosis of Graves’ disease
[72,92].
Thyroid storm
Thyroid storm is a rare medical emergency, characterized by an
extreme hypermetabolic state precipitated by high levels of en-
dogenous thyroid hormones. It occurs in 1% of women with
untreated or inadequately treated hyperthyroidism during preg-
nancy and has a high risk of maternal heart failure [93], shock, stupor
and coma, as well as a maternal mortality of up to 25% [70,94,95].
Thyroid storm should be suspected in every pregnant woman with
pre-existing hyperthyroidismwho presents with unexplained fever,
altered mental status, cardiac arrhythmias, confusion, and sei-
zures [94]. Often there is an identiﬁed precipitating factor, such as
infection, surgery, labour or delivery.
Its treatment does not differ from non-pregnant women and it
should be managed by a multidisciplinary team consisting of en-
docrinologists and fetal specialists in the intensive care unit with
continuous fetal monitoring if the fetus has reached 26 weeks of
gestational age [94,95]. Prompt recognition and management is
paramount.
The pharmacological treatment is directed against thyroid
hormone synthesis and secretion as well as the peripheral action
of thyroid hormone at the tissue level. A multimodality treatment
approach should be employed, including beta-adrenergic block-
ade (propranolol), high doses of PTU, inorganic iodide and
corticosteroid therapy (dexamethasone). In addition to the phar-
macological management, general supportive care should be
undertaken such as oxygen administration, antipyretics, cooling blan-
kets, volume resuscitation, nutritional support, respiratory care and
monitoring in an intensive care [70]. In general, it is recom-
mended to avoid delivery in the presence of thyroid storm unless
fetal indications for delivery outweigh the risks to thewoman [94,95].
Autoimmune thyroid disease
Maternal TSH does not cross the placenta; however, maternal
T4 and T3 do cross the placenta in small quantities and are impor-
tant for early fetal growth. TRAbsmay cross the placenta and directly
stimulate the fetal thyroid when present in high concentrations. TPO
antibodies per se are not known to directly damage the foetus, but
are considered indicative of an immune dysfunction and increase
the risk of maternal thyroid dysfunction.
Maternal TSH receptor antibodies
TRAb titre decreases as the pregnancy progresses. Fetal hyper-
thyroidism due to maternal TRAb stimulation is rare with a reported
rate of 1 in 4000–40,000 pregnancies [96].
It is recommended that TRAb should be checked at 20–26weeks
of gestation (Table 4), albeit fetal Graves’ disease has been re-
ported as early as 18 weeks gestation [97]. Women with TRAb titres
two-to-three-fold above the normal level and women treated with
ATD should have TFTs performed and the fetal thyroid appear-
ances checked during the fetal anatomy ultrasound at 20 weeks of
gestation; these should be repeated every 4–6weeks thereafter [66].
Features suggestive of fetal thyroid dysfunction include goitre, growth
restriction, hydrops, tachycardia or heart failure [98]. Umbilical cord
sampling should be used as a last resort and only be considered if
the diagnosis of fetal thyroid disease remains uncertain with the
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available clinical and sonographic data, and only if such an inva-
sive test could potentially change the management given that this
procedure itself carries a non-trivial risk of fetal loss. If fetal hy-
perthyroidism is present and is thought to endanger the pregnancy,
ATD should be given to the mother to suppress the fetal thyroid.
This represents the only potential indication for concomitant use
of ATD and levothyroxine (‘block and replace’ regime) in pregnancy.
Maternal thyroid peroxidase antibodies
Women of reproductive age have a prevalence of TPOAb of 6–20%
[99]; these are strongly associated with polyhydramnios [100], pre-
mature rupture of membranes, low birth weight [49], and preterm
delivery. Thyroid autoimmunity is also associated with increased
risk of miscarriage even in euthyroid, iodine suﬃcient popula-
tions [40]. Nevertheless, thyroid autoimmunity and subclinical
hypothyroidism seem to act synergistically to multiply the risk of
miscarriage, which overall takes place at an earlier stage in gesta-
tion compared to unaffected women [40]. In a meta-analysis of case-
control and cohort studies euthyroid women with elevated TPO
autoantibodies were reported to have a two-to-four-fold higher risk
of spontaneous miscarriage, three-fold higher risk of subfertility and
a two-fold higher risk of preterm birth than those without [101].
One study reported that levothyroxine treatment in the ﬁrst tri-
mester reduces miscarriages in euthyroid TPOAb-positive women
[50]. However, it had a small sample size and as previously men-
tioned levothyroxine initiation was late. At present there is
insuﬃcient evidence to recommend for or against screening for
thyroid antibodies, or treatment with levothyroxine during the ﬁrst
trimester of pregnancy in euthyroid women, or those with sporad-
ic or recurrent miscarriages, or in women undergoing in vitro
fertilisation [8]. The Endocrine Society made a somewhat more stern
statement that it cannot recommend screening or treatment with
thyroxine in such circumstances [9] (Table 3).
Nevertheless, women identiﬁed as TPOAb positive should have
TFTs checked before pregnancy and during the ﬁrst and second tri-
mester, as they are at increased risk of developing subclinical or overt
hypothyroidism; these women can be monitored as per overt/
subclinical hypothyroidism recommendations for simplicity [8].
Recurrent pregnancy loss has been correlated with reduced se-
lenium levels and selenium supplementation may reduce thyroid
antibody levels in euthyroid patients [102,103]. Indeed, when
selenomethionine was given to euthyroid pregnant women with
TPOAb positivity, TPOAb titers reduced more steeply as the gesta-
tion progressed and the incidence of post-partum thyroid dysfunction
and hypothyroidism diminished [102]. However, the sample size was
small (85women in the intervention group) and it involved an Italian
population alone.
Therefore, further RCTs are needed to investigate the effects on
the maternal and neonatal outcomes when levothyroxine or sele-
nium or other treatments are given to pregnant euthyroid women
with positive thyroid antibodies and two such RCTs are currently
underway: a randomised controlled trial of the eﬃcacy and
mechanism of levothyroxine treatment on pregnancy and
neonatal outcomes in women with thyroid antibodies (TABLET:
Thyroid AntiBodies and LEvoThyroxine study; https://www
.clinicaltrialsregister.eu/ctr-search/trial/2011–000719-19/GB), and
a randomised controlled trial of levothyroxine for euthyroid women
with recurrent miscarriage and thyroid autoimmunity (T4Life
trial; https://www.clinicaltrialsregister.eu/ctr-search/trial/2011
–001820-39/DK).
Postpartum thyroiditis
The prevalence of postpartum thyroiditis varies from 1% to 17%
and ismore common inwomenwith type 1 diabetes, a family history
of hypothyroidism and in euthyroid pregnant women with TPOAb
positivity [50,100]. Given that autoimmune thyroid disease mainly
revolves around cell-mediated autoimmunity and the fact that preg-
nancy diminishes cellular immunity, it frequently improves during
pregnancy. During the post-partum period relative hypocortisolism
seems critical for the development of autoimmune thyroid disease
via a disinhibition of speciﬁc cytokine production (e.g. TNFα, IL-
12 and IFNγ); the relative reduction in sex steroids is also a likely
contributing factor [104].
The classical pattern of postpartum thyroiditis is characterized
by transient thyrotoxicosis followed by transient or, in 5% of cases
permanent, hypothyroidism, before a return into a euthyroid state,
usuallywithin the 12-month post-partumperiod. Two thirds of pa-
tients with TPOAb positivity can be expected to present with the
classical formof the disease,whereas two thirds of thosewith absent
TPOAb will present with isolated thyrotoxicosis [100]; presenta-
tion with isolated hypothyroidism is also common [70]. Post-
partum thyroiditis usually presents clinically between three and four
months postpartum but may be delayed to as long as six months,
[66]which iswhen the TPOAb titers are expected to be at their peak.
The diagnosis is made on clinical and biochemical grounds. A dis-
tinction should bemade fromGraves’ disease, for example the latter
may have a bigger goitre, a bruit on auscultation, Graves’ ophthal-
mopathy and high TRAb levels. Radioactive iodine or technetium
uptake tests can help distinguish between postpartum thyroiditis
(lowuptake) andGraves’ disease (high uptake); they need to be used
with caution if women are breast-feeding; they should be in-
structed to pump and discard breast milk for 10 half-lives i.e. for
three and ﬁve days with 99 m-Tc-pertechnetate and 123-Iodine,
Table 4
Guidelines & recommendations on the use of Thyroid Receptor Antibodies (TRAb)
during pregnancy.
Guidelines & recommendations on the
use of Thyroid Receptor Antibodies
(TRAb) during pregnancy
American Thyroid
Association (ATA) 2011
[8]
22–24/40 if previous medical history of
Graves’ disease
The Endocrine Society
(TES) [9]
22/40 if previous history or active
Graves’ disease, if prior radioactive
iodine (RAI) therapy or thyroidectomy,
previous neonate with Graves’ disease or
previously raised TRAb
If TRAb negative and not on anti-thyroid
drugs, then there is very low risk of fetal
or neonatal thyroid dysfunction
Italian Thyroid Association
(AIT) & Italian
Association
of Clinical
Endocrinologists (AME)
[113]
Early pregnancy and 22–26/40 if on anti-
thyroid drugs for active Graves’ disease
and if recent radioidine therapy
22–26/40 only if previous Graves’
disease (and no relapse in pregnancy)
and if surgically treated >1 year before
pregnancy onset
American Thyroid
Association (ATA) 2016
[70]
First trimester and if raised re-check
again at 18–22/40 if prior radioactive
iodine therapy or thyroidectomy
Initial pregnancy visit or at diagnosis and
if raised again at 18–22/40 for active
Graves’ disease requiring ATD or new
Graves’ disease in pregnancy. If TRAb
raised at 18–22/40 then re-check at
30–34/40
Beware of the speciﬁc assay used locally and also about the fact that TRAb assays
do not routinely measure antibody activity. However sensitive bioassays do exist that
measure antibody activity and these can be used in exceptional circumstances e.g.
in a pregnant woman with no thyroid gland in situ but positive TRAb, in order to
know whether these are stimulating or inhibiting antibodies.
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respectively [70]. Thyroid ultrasound scanning can provide further
evidence of its presence; classic appearances include focal or diffuse
non-speciﬁc hypoechogenicitywhich resolves on serial scanning and
reducedﬂowonpowerDoppler comparedwith lesshypoechogenicity
and an increased blood ﬂow (including ‘thyroid inferno’) often ob-
servedwithGraves’ disease. The sonographer also needs to be aware
that an inﬂamed thyroid gland and associated reactive lymph nodes
can give appearances that mimic neoplastic disease [105]. Finally,
it is worth mentioning that the spectrum of disease in association
with thyroid autoimmunityhas expanded in recent years, for example
post-partum depression and alexithymia and even psychosis have
beendirectly linkedwith thyroid autoimmunity [106–108]. However,
no association was noted in a large Norwegian population-based
study between anxiety and depression and thyroid autoimmunity
[109]. Moreover, there is RCT evidence that the use of levothyroxine
in TPO-Ab positive women from 6 weeks to 6 months post-partum
did not reduce the risk of occurrence of post-natal depression [110].
Treatment of post-partum thyroiditis
The management of postpartum thyroiditis should be deter-
mined by the degree of clinical symptoms rather than the severity
of the abnormal biochemistry. The thyrotoxic phase may be treated
with beta-blockers (propranolol or metoprolol) for symptom control;
ATD are ineffective given that post-partum thyroiditis does not rep-
resent a state of increased thyroid hormone synthesis and secretion,
hence there is no role for drugs that block thyroid hormone
synthesis. Close monitoring is the key to its management. If hypo-
thyroidism develops then treatment is only indicated if this is
persistent and/or symptomatic. The TFTs trend is helpful in guiding
treatment decisions. For example, if the fT4 is low but slowly rising
and the patient is asymptomatic then no treatment is required. It
is recommended that women with postpartum thyroiditis should
be monitored with annual TSH and fT4 measurements [111] and
in the post-partum period of future pregnancies given the high risk
of recurrence (up to 70% [112]).
Conclusions
Early diagnosis and management of thyroid dysfunction in preg-
nancy is essential to avoid adverse maternal and fetal outcomes.
Overt hypothyroidism and hyperthyroidism should be treated ap-
propriately. Subclinical hypothyroidism is often treated with
levothyroxine, although it has not been proven beyond doubt that
it improves maternal or fetal outcomes. Subclinical hyperthyroid-
ism does not usually require treatment and the possibility of non-
thyroidal illness or gestational thyrotoxicosis should be considered.
Despite the demonstrated adverse maternal and fetal outcomes in
observational studies with euthyroid women having positive thyroid
autoantibodies, to date there is insuﬃcient data to prove that such
outcomes improve with thyroxine supplementation. Further RCTs
are required to investigate the effects of treating pregnant euthy-
roid women with autoimmune thyroid disease and, indeed, women
with subclinical hypothyroidism and isolated hypothyroxinaemia.
Current practice guidelines provide a safe framework for practice
and havemany similarities among them, as well as differences which
generally indicate gaps in our current knowledge of thyroid disor-
ders in pregnancy.
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